Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients a 1 year and older, and in adults.
In 2023, total prescription medicine use increased by 3% and reached 210 billion days of therapy, per IQVIA's Use of Medicines in the U.S. 2024 report.